Abstract
Background
The aim of the present study was to evaluate the physical properties of “admixture paste”, which is a commercially available gel containing hinokitiol for use against severe stomatitis, and its characteristics as a moisturizing gel and denture adhesive.
Methods
The admixture paste, which contained dexamethasone (Dexaltin®), gel for oral care (Refrecare H®) and petrolatum, and its 3 components, either alone or in different combinations, were subjected to viscosity, adhesiveness and elution testing to compare their physical properties. Viscosity was measured with a stress-controlled rheometer. Adhesive force was measured by tension test. Elution under a simulated oral environment was evaluated by monitoring with a fixed-point camera and absorbance. Both adhesiveness and elution were evaluated every hour for 6 h. A linear mixed-effects model was used to assess differences in the time course of elution between samples. In 3 og-rank test was used to compare time to elution into saliva among samples.
Results
The results of viscosity testing demonstrated that the admixture paste had similar viscosity to cream-type denture adhesives and this was temperature independent. In the adhesiveness tests, the admixture paste showed stronger adhesiveness than that of cream-type denture adhesives. In the elution test, the admixture paste demonstrated gradual dissolution and apparent temporal changes for 6 h in a simulated oral environment.
Conclusions
The results of the present study demonstrated that the admixture paste has adhesive force similar to those of denture adhesives and good local retention in saliva, and that it might be suitable for therapeutic use in patients with severe stomatitis derived from radiotherapy and/or chemotherapy for cancer.
Electronic supplementary material
The online version of this article (10.1186/s12885-018-4017-2) contains supplementary material, which is available to authorized users.
Keywords: Stomatitis, Head-and-neck cancer, Treatment paste, Denture adhesives, Radiotherapy and/or chemotherapy
Background
Multidisciplinary treatments consisting of surgery, radiotherapy and chemotherapy are performed for patients with malignancy [1]. However, these treatments can induce severe oral stomatitis, thus interfering with oral ingestion. In our daily clinical practice, we frequently encounter patients undergoing treatment by radiotherapy and/or chemotherapy (hereinafter referred to as “CRT”) for cancer in the head and neck region with severe oral stomatitis. Radiotherapy for head and neck cancer has a nearly 100% risk of causing oral stomatitis in the irradiated area [2, 3]. Chemotherapy is also associated with a 1–10% risk of causing severe oral stomatitis [4, 5]. However, there is no established pre-treatment management practice for preventing stomatitis, as the method of treatment for stomatitis varies between institutions [6].
At the Department of Dentistry and Oral Surgery in the College of Medicine, we provide pre-operative oral management for almost all patients with head and neck cancer among those who are hospitalized. For stomatitis occurring in these patients after CRT, we perform oral management practices, such as oral cleaning, application of gel for oral care, laser treatment and use of mouthwash containing local anesthetic. Many of the patients with head and neck cancer are elderly and have postoperative defects of teeth, jaw bone and oral tissue, which is necessary for the use of oral appliances such as removable dentures and palatal augmentation prosthesis (PAP) [7]. Thus, there are many patients who experience severe stomatitis including mucositis, which interferes with the use of dentures during CRT. The interruption of oral appliance use significantly affects quality of life (QOL) by preventing patients from talking and eating [8–10]. Severe stomatitis may result in interruption or even discontinuation of cancer treatment [11] by infections derived from severe oral stomatitis, neutropenia and/or uncontrollable pain. Nevertheless, no established treatment is currently available for severe stomatitis in patients undergoing head-and-neck cancer CRT with oral appliances. Dexamethasone ointment and other steroid ointments are often prescribed for the purpose of pain relief, but indiscriminate use of these agents may induce microbial substitution with Candida and other fungi [12, 13]. Furthermore, steroid ointments are effective against oral stomatitis caused by head-and-neck cancer treatments such as CRT [14]. Gel for oral care is often prescribed for pain relief and to moisten the oral cavity. In general treatment, all of these components are used separately, but not simultaneously.
In our clinical practice, we found that dexamethasone and oral gel with hinokitiol are effective when mixed together because the viscosity is increased. Vaseline is added to further adjust the viscosity, which improves the handling. Subsequently, we mixed various ointments and oral gels for use against oral stomatitis with the aim of finding a paste having an appropriate coefficient of viscosity. As a consequence, we developed an “admixture paste” formulated from equal amounts of dexamethasone ointment (Dexaltin® Oral Ointment, Nippon Kayaku Co., Ltd., Tokyo, Japan; hereinafter referred to as “Dexi”), gel for oral care (Refrecare® H, Nippon Zettoc Co., Ltd., Tokyo, Japan; “Moist”) and petrolatum (Kenei Seiyaku, Osaka, Japan; “Vase”) for infection prevention and symptom relief of severe stomatitis in patients with head and neck cancer. With this paste, we expect good local retention and lasting drug/gel efficacy regardless of the flow of saliva.
For clinical use of “admixture paste”, we obtained approval from the Hyogo College of Medicine Ethics Committee regarding the safety and approach used. Subsequently, the admixture paste was available for short-term (maximal 3 weeks) treatment of severe stomatitis in patients undergoing head-and-neck cancer CRT and using oral appliances (dentures and PAP). Short-term use of the admixture paste for head and neck cancer with severe stomatitis resulted in symptom relief of severe stomatitis and appeared to provide stability of oral appliances. We have not yet performed quantitative assessment of the physical properties (viscosity and elution characteristics to saliva) of this admixture paste.
The aim of the study was to evaluate the physical properties and moisturizing characteristics of “admixture paste” (containing dexamethasone, gel for oral care and petrolatum), which has a viscosity and adhesiveness equivalent to that of denture adhesive.
Methods
Preparation of mixed paste
The components of the admixture paste and their compositions are shown in Table 1. The admixture paste was prepared by mixing equal volumes of Dexi, Moist and Vase in a rubber cup for dental use (28 mm in inner diameter and 33 mm in height; Tokuyama Dental, Osaka, Japan) using a metal spatula (YDM Corporation, Tokyo, Japan) for 30 s until a homogeneous knead was obtained. Kneading was performed by either a dentist or a dental hygienist. The obtained admixture paste was stored in an airtight container at room temperature for up to 24 h before use. An additional movie file shows the paste preparation in more detail (see Additional file 1).
Table 1.
Dexi | Moist | Vase | |||
---|---|---|---|---|---|
Active component | Dexamethasone | Active component | Hinokitiol Dipotassium glycyrrhizinate |
Active component | White vaseline |
Additive | Liquid paraffin Sodium polyacrylate Plastibase |
Sweetener | Xylitol | ||
Solubilizing agent | Polyoxyethylene hydrogenated castor oil | ||||
Preservative | Sodium benzoate | ||||
Preservative | A hydrogenphosphate melanian snail thorium Citric acid Humecant sodium hyaluronate (2) Concentrated glycerin A propylene glycol |
||||
Solvent | Purified water Ethanol |
||||
Binding agent | Sodium polyacrylate A carrageenan |
||||
Stabilizer | An edetic acid melanian snail thorium | ||||
Flavor | Rifrecare H and menthol |
Dexi: dexamethasone ointment (Dexaltin® Oral Ointment); Moist: gel for oral care (Refrecare H®); Vase: petrolatum
Physical property evaluation
Viscosity measurement
Viscosity was measured with a stress-controlled rheometer (Anton-Paar Japan, Tokyo, Japan) on the following 8 materials: Dexi+Moist+Vase (DMV; i.e., admixture paste), Dexi, Dexi+Moist (DM), Moist, Moist+Vase (MV), Vase, cream-type denture adhesive New Poligrip® (GlaxoSmithKline K.K., Tokyo, Japan; hereinafter referred to as “Poli”) and cushion-type denture adhesive Toughgrip (Kobayashi Pharmaceutical Co., Ltd., Osaka, Japan; “Tough”). We prepared fresh DMV for each experiment. Viscosity η [Pa·s] and shear stress σ [Pa] were measured at two temperatures (25 °C and 37 °C to mimic room and oral temperatures, respectively) at shear rates (dγ/dt) varying from 0 to 30 s− 1. Originally, the method for viscosity measurement basically followed Japanese Industrial Standards (JISK7117–2). However, the aim of rheological measurement in the present study was to describe how the newly proposed material deforms with the application of force and to compare this with other well-known materials. In this research, we therefore measured viscosity at exponentially increasing shear stress levels. Figure 1 shows an explanation of viscosity and how it is plotted on a graph.
Adhesive force measurement
The measurement of adhesive force was performed on three types of sample, i.e., Poli, Tough and DMV, which were stored for up to 6 h in a simulated oral environment. Figure 2 shows the experimental procedure. Each sample having a roughly constant volume of 0.024 ml is squeezed between two stainless steel disks (SUS304; diameter, 35 mm; thickness, 1 mm). As two pieces of scotch tape are superposed on the bottom disk, the gap between the disks should be constant at 0.12 mm for all experiments. Subsequently, the cross-sectional area of the squeezed sample was constant at 200 mm2. The disks were then immersed in artificial saliva (Saliveht; Teijin Pharma Ltd., Tokyo, Japan) and incubated in an FMS-1000 thermostatic chamber (Tokyo Rikakikai Co., Ltd., Tokyo, Japan) at 37 °C while shaking at 37 rpm (MMS-3010; Tokyo Rikakikai Co., Ltd., Tokyo, Japan). Saliveht, which can only be prescribed in Japan, was used as artificial saliva throughout all experiments, and was treated with a Vacuum mixer (J. Morita Corporation, Tokyo, Japan) in order to remove CO2.
The bottom disk was firmly fixed onto a fixed glass disk using glue, while a hook was fixed on the top disk using strong double-side tape. A hanging weight scale (Electronic Portable Luggage Digital Scale, accuracy, 5 g; Weiheng, Shenzhen, China) was hitched to the hook attached to the top disk in order to measure the changes in normal force as a weight change. The normal force increased gradually as the top disk was stuck to the sample. However, the normal force instantaneously decreased when the top disk was separated from the sample. The hanging scale was manually pulled at a sufficiently slow and constant speed, such that the digits of the scale changed slowly to clearly see the maximum, and that the effect of acceleration on the measured value is negligible. The maximum normal force was determined from digit changes while pulling the scale. The adhesive force was divided by the cross-sectional area of the sample in order to account for the effects of variations in sample volume.
An additional movie file shows this experimental procedure in more detail (see Additional File 2).
In order to ensure the reproducibility of the adhesive force measurement, we prepared DMV samples three times, and repeated the measurement 15 times per each. The result indicates that we could prepare DMV with experimental error less than 10%, and the variation between samples was 50% of mean values. Since the variation was smaller than the difference of mean value between other two samples. Thus in this experiment, one sample was measured per condition.
Elution tests under simulated oral environment
Each material was mixed with a blue water-soluble ink (THC-7C4N; Elecom, Osaka, Japan), kneaded and placed in a well of a 96-well tissue culture microplate (Iwaki, Tokyo, Japan) filled to a level that ensured all samples were at an equal volume. Each of the paste-filled wells was transferred to the wells of a 12-well tissue culture microplate (Iwaki), to which 5 ml of artificial saliva (Saliveht) was added. The above-mentioned micro-plate was used to prepare 6 sets, and was then placed on a PSU-2 T shaker (Waken B Tech Co., Ltd., Kyoto, Japan) and incubated in an FMS-1000 thermostatic chamber (Tokyo Rikakikai Co., Ltd., Tokyo, Japan) at 37 °C for 1–6 h while shaking at 37 rpm to test for elution of each material under conditions similar to the oral environment. Elution monitoring with a fixed-point camera was started immediately after addition of artificial saliva, and images were obtained after every hour.
Every hour, supernatant was collected from each well, and was transferred to a 96-well multiplate (200 μL per well). Absorbance at 535 nm was measured in triplicate for each sample in a SPECTRAmax (A) microplate reader (Molecular Devices Japan K.K., Tokyo, Japan). We performed measurements three times for each sample. Differences in the time course of elution between samples were assessed using a linear mixed-effects model with the main effects of time and group, and their interaction effect, as fixed effects, followed by post-hoc analyses to examine time course changes and sample differences. The time effect was treated as categorical. In addition, time to elution into saliva was compared among the samples using a log-rank test. Elution of the sample into saliva was defined as absorbance being more than 0.02, which was determined based on the absorbance of water-insoluble materials (cushion-type denture adhesive (Tough) and petrolatum (Vase)). All statistical analyses were performed using SPSS statistics version 22.0 software (IBM, Armonk, NY).
Results
Viscosity measurement
The results of viscosity measurement are shown in Fig. 3. This graph shows the change of the relative difficulty of altering the shape of the sample with increasing force applied to each sample; viscosity increases with the values on the vertical axis.
DMV maintained a constant level of viscosity up to a certain level of stress, showing a stress-dependent pattern similar to that of Poli. However, both DMV and Poli showed marked decreases in viscosity under extreme stress. DMV showed a consistent level of viscosity at varying temperatures, as observed with Dexi, Moist and Tough, demonstrating its temperature independence. Tough showed neither stress nor temperature dependence, with its level of viscosity being slightly lower than those of the other materials and comparable to that of DMV under extreme stress. These findings indicate that DMV has combined properties of Poli and Tough. Furthermore, none of the components of DMV alone showed such properties. The timing of fluidity increases in DMV was almost the same as that in Poli.
Adhesive force measurement
The results of adhesiveness tests are shown in Fig. 4. With regard to the 6 h temporal change, the temporal adhesion force changes for every sample were different, but the adhesive force maintained the same order of Tough>DMV > Poli. This suggests that the DMV showed stronger adhesiveness when compared with cream-type denture adhesives and weaker adhesiveness when compared with cushion-type denture adhesive in the oral environment. In the oral environment, we found that the adhesive stress of DMV falls between that of Poli and that of Tough, and this rank order (Tough>DMV > Poli) did not change after 6 h.
Elution tests
The results of the elution tests using the microplate setting are shown in Figs. 5 and 6. Linear mixed-effect model analysis demonstrated a significant difference in the time course of elution between the samples (p-value< 0.001 for interaction between time and group), the elution being increased in four samples (DM, Poli, Moist and Dexi), but not in the other four samples. The highest elution rate was observed for DM, followed in descending order by Poli, Moist, Dexi, MV, DMV, Vase and Tough. The elution of DMV was relatively stable. DMV showed similar temporal changes in elution as Vase (without significant differences between DMV and Vase). The log-rank test showed that there was a significant difference among the samples (p < .0001). This suggests that DMV gradually dissolves and remains firm for 6 h in the oral environment, and is comparable to paste with a greasy base. While no elution was observed with Tough, DMV maintained slight elution in artificial saliva for 6 h, suggesting that DMV has good moisture retention while maintaining the long-term steroid elution and helping to protect the affected area.
Discussion
Methodological considerations
The reasons for selecting the present components for the paste were as follows: steroid ointment is effective for pain relief in oral stomatitis [12, 13]; oral gel ameliorates the xerostomia occurring in head and neck cancer CRT [15, 16]; and Vaseline is a safe modifier for viscosity [17].
Admixture of the three agents (Dexi/Moist/Vase) yielded a mixed paste that was stickier than any single component or 2-component mixtures (Fig. 3), and this property did not show temperature dependence. These results may be explained as follows. Plastibase (Table 1), which is present in Dexi, is used to decrease temperature dependence (“Dexi”; Fig. 3B). On the other hand, although Dexi and Moist alone show temperature independence (Fig. 3B,D), temperature dependence was observed when mixing these two components (“DM”; Fig. 3C). It is possible that the sodium polyacrylate (superabsorbent polymer) present in Moist leads to temperature dependence, as it possesses hydrophilic and hydrophobic groups, causing it to desorb at high temperatures, thereby inducing viscosity changes [18].
The reason for the temporal change at 6 h is as follows: the interval between meals is about 6 h at most, as the majority of patients using an oral appliance would clean the oral appliance after each meal. As the mixed paste (DM, DV, MV and DMV) components were not quantitatively analyzed for subsidiary ingredients, we are uncertain whether such components exhibited effects on temperature dependence. However, the sodium polyacrylate present in Moist is associated with temperature changes, and when it was mixed with Dexi, viscosity might have changed with temperature.
Sodium polyacrylate is a type of superabsorbent polymer having a hydrophilic carboxyl group, and it forms a gel structure to incorporate a large number of water molecules into the meshwork [19, 20]. After mixing the three components, the balance of hydrophilic and hydrophobic groups changed, particularly due to the oil and fat components of the Vaseline, forming a gelatinous structure, which may have increased viscosity to a greater degree than expected.
The adhesiveness of the DMV was as stable as a commercial denture adhesive for 6 h. Based on the results in Fig. 4, we show that DMV has sufficient adhesive stress as a denture adhesive, and that DMV would be a useful denture adhesive. The DM samples mixed with gel-like structures were easily dissolved in artificial saliva (Fig. 6). On the other hand, when DM and Vase were mixed, the action of Vaseline’s hydrophobic groups was potent, and elution to artificial saliva of the DMV was significantly lower than DM. This suggests that DMV has long-term steroid efficacy and local retention in the oral environment. We cannot explain the reasons for the poor dissolution and persistent adhesiveness under a simulated oral environment in this paper. We believe that both the characteristics of sodium polyacrylate (containing Moist) and the osmotic pressure of artificial saliva (including NaCl) influenced our results. Miwa et al. reported that in artificial saliva, samples with a Vaseline base did not elute to saliva [21]. In addition, because the suction force of sodium polyacrylate, the gelling agent, included in Moist decreases on mixing with Dexi, temporal changes may have occurred. However, these physical properties require further investigation.
Clinical application of admixture paste
In this paper, for a small number of patients, we applied admixture paste for the treatment of stomatitis. Subjective pain in DMV-treated patients was improved or unchanged, and slight macroscopic changes in stomatitis were seen. In addition, we have no data on a control group (patients without DMV-use) at this time, or sufficient data on the clinical use of DMV to confirm its clinical benefit. In Additional File 3, we show our clinical trial results to date, and we will present further results in the future.
Dexamethasone ointment is indicated for refractory stomatitis according to the package insert. In fact, steroid application is not typically the first-choice treatment for stomatitis. However, this admixture paste contains hinokitiol, the active ingredient in Refrecare H®, which has been shown to exert anti-microbial activity against Candida and to inhibit biofilm formation [22, 23].
The admixture paste has physical properties similar to those of denture adhesives and was developed with the intention of using it in denture-wearing patients. In patients with head and neck cancer, severe stomatitis may occur in both the oral cavity and in the pharynx. The latter often causes contact/swallowing pain and thereby prevents oral food intake [6, 24]. Denture use has been shown to be effective in improving mastication/swallowing disorder, increasing chewing-stimulated salivary secretion [25, 26] and preventing disuse atrophy of surrounding tissue in the head and neck [27]. The present admixture paste may therefore contribute to the maintenance of patient QOL by treating severe stomatitis and allowing them to use their oral appliances.
Meanwhile, the admixture paste contains dexamethasone, a steroid, and thus has a risk of inducing microbial substitution on long-term use. Its use should therefore be limited in patients with immune systems that have been compromised by CRT [12, 28]. At the same time, it has been shown to be highly effective in treating oral mucosal lesions, particularly for the relief of pain [29]. Dexamethasone is a steroidal agent and is generally recommended for use in aphthae or refractory stomatitis. Frequent monitoring of adverse reactions and worsening of symptoms by an oral surgeon is therefore recommended. As a future clinical theme, we believe that we need to examine the efficacy and safety of this admixture paste.
Study limitations
There are some limitations in our research: an elution of admixture paste was exploratorily evaluated with no sample size calculation in advance; the adhesive force evaluation was performed with a single sample, which did not allow to make statistical comparisons and therefore compare differences. Thus, in the future, to demonstrate the hypothesis that admixture paste has an adhesiveness similar to that of denture adhesive and has gradual solubility, a behavioral study should be carried out over time, with a planned sample size.
Conclusion
The application of admixture paste (mixture of dexamethasone, gel for oral care and petrolatum) for severe stomatitis in patients with head and neck cancer may facilitate oral food intake while using an oral appliance through its high levels of local retention, adhesiveness and gradual solubility in oral environment, which are not achieved with any of the 3 components alone.
Additional files
Acknowledgements
The authors would like to express their sincere appreciation to K. Yoshikiyo, M. Shiramizu, and K. Yasukawa for their tremendous support.
Funding
None.
Availability of data and materials
The materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, by contacting the corresponding author, without breaching patient confidentiality.
Abbreviations
- CRT
Radiotherapy and/or chemotherapy
- Dexi
Dexamethasone
- DM
Mixed paste consisting of dexamethasone and gel for oral care
- DMV
Mixed paste consisting of dexamethasone, gel for oral care and petrolatum
- Moist
Gel for oral care
- MV
Mixed paste consisting of gel for oral care and petrolatum
- PAP
Palatal augmentation prosthesis
- Poli
Cream-type denture adhesive: New Poligrip®
- QOL
Quality of life
- Tough
Cushion-type denture adhesive: Toughgrip
- Vase
Petrolatum
Authors’ contributions
YH, MA, SH and HK made substantial contributions in the conception and design of the study. KS, KH, MK, YK, JS and KY participated in data collection and analysis for experimental records. AS, YK and SH were involved in drafting the manuscript. YH and HK helped to draft and carefully revise the manuscript. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
The present study was performed with the approval of the ethics committee of Hyogo College of Medicine (H27–1976). All patients provided their written informed consent to participate in this study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
Electronic supplementary material
The online version of this article (10.1186/s12885-018-4017-2) contains supplementary material, which is available to authorized users.
Contributor Information
Ayumi Sakuramoto, Email: ayu.cherry.ayu@gmail.com.
Yoko Hasegawa, Phone: +81-798-45-6677, Email: cem17150@hyo-med.ac.jp.
Kazuma Sugahara, Email: kazumaro0526@gmail.com.
Yoshiyuki Komoda, Email: komoda@kobe-u.ac.jp.
Kana Hasegawa, Email: ka-hasegawa@hyo-med.ac.jp.
Shinichi Hikasa, Email: ykhikasa@hyo-med.ac.jp.
Mai Kurashita, Email: elmarlimpio@gmail.com.
Junya Sakai, Email: j-sakai@hyo-med.ac.jp.
Masahiro Arita, Email: m-arita@kyu-dent.ac.jp.
Kazuhiro Yasukawa, Email: k.yasukawa@teijin.co.jp.
Hiromitsu Kishimoto, Email: kisihiro@hyo-med.ac.jp.
References
- 1.Beck TN, Golemis EA. Genomic insights into head and neck cancer. Cancers of the Head & Neck. 2016;1(1) [DOI] [PMC free article] [PubMed]
- 2.Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(Suppl 9):1995–2025. doi: 10.1002/cncr.20162. [DOI] [PubMed] [Google Scholar]
- 3.Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831. doi: 10.1002/cncr.22484. [DOI] [PubMed] [Google Scholar]
- 4.Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin N Am. 2008;52:61–77. doi: 10.1016/j.cden.2007.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kishimoto H. The oral management in the cancer medical care; we prevent complications and aim at the improvement of a treatment outcome and the quality of life. Journal of Hyogo college of. Medicine. 2014;39:25–29. [Google Scholar]
- 6.Katou K. Nutrition support and oral Care for Head and Neck Cancer Patients Undergoing Chemoradiotherapy. Head and Neck Cancer Frontier. 2014;2:48–51. [Google Scholar]
- 7.Valente VB, Takamiya AS, Ferreira LL, Felipini RC, Biasoli ÉR, Miyahara GI, et al. Oral squamous cell carcinoma misdiagnosed as a denture-related traumatic ulcer: a clinical report. J Prosthet Dent. 2016;115:259–262. doi: 10.1016/j.prosdent.2015.08.024. [DOI] [PubMed] [Google Scholar]
- 8.Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113:2704–2713. doi: 10.1002/cncr.23898. [DOI] [PubMed] [Google Scholar]
- 9.Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531–1539. doi: 10.1002/cncr.11671. [DOI] [PubMed] [Google Scholar]
- 10.Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46(6):452. doi: 10.1016/j.oraloncology.2010.03.012. [DOI] [PubMed] [Google Scholar]
- 11.Mizukami N, Ymauchi M, Watanabe A, Danzuka K, Sato T, Oomori K, et al. Satisfaction survey of pain management for severe mucositis caused by cancer therapy for head and neck cancer. Palliative Care Res. 2012;7:408–414. doi: 10.2512/jspm.7.408. [DOI] [Google Scholar]
- 12.Arizumi M, Ikemura Y, Tanabe K. Clinical Evaluation of new-type Aphtasolon (dexamethasone) on stomatitis. Oral therapeutics and. Pharmacology. 1985;4:28–40. [Google Scholar]
- 13.Takeuchi-Igarashi H, Ito H, Numabe Y. A case report of moderate periodontitis with chronic desquamative gingivitis. Journal of the Japanese Society of Periodontology. 2012;54:183–192. doi: 10.2329/perio.54.183. [DOI] [Google Scholar]
- 14.Teshima A, Tyatani M, Inoue T. Effectiveness of Kenarogu ointment to radiation stomatitis of head and neck cancer patients, study of safety. Japanese Pharmacology & Therapeutics. 1986;14:7163–7166. [Google Scholar]
- 15.Watanabe T. Perioperative Oral care in cancer patient. The bulletin of Tsurumi college Pt 3, studies in infant education and. dental hygiene. 2013;50:49–52. [Google Scholar]
- 16.Kishimoto H. Oral Management for cancer patients undergoing chemotherapy and/or radiotherapy. Journal of. Clin Exp Med. 2012;243:657–662. [Google Scholar]
- 17.Fukami T, Yamamoto Y, Nakamura Y, Kamano M, Umeda Y, Makimura M, et al. Quality testing of steroidal ointment mixed with white petrolatum : rheological properties and stability testing. Jpn J Pharm Health Care Sci. 2006;32(9):964. doi: 10.5649/jjphcs.32.964. [DOI] [Google Scholar]
- 18.Aoyama M. Adsorption behavior during the clay suspension of the acrylic acid-based polymer. Trend. 1999:20–6.
- 19.Harada M. Japanese Standard of Food Additives explanatory note. vol. 3th. Kinpara publication;1974.p.805.
- 20.Masuda F. Some Charactors of hydrogel from super absorbent polymer. J Jpn Soc Colour Mater. 1986;59:221–226. doi: 10.4011/shikizai1937.59.221. [DOI] [Google Scholar]
- 21.Miwa Y, Yamaji A, Miki Y, Kimura S, Okada H. The basic study on dissolution behavior of dental drugs. Oral therapeutics and. Pharmacology. 1991;10:127–132. [Google Scholar]
- 22.Nakamura M, Fujibayashi T, Tominaga A, Satoh N, Kawarai T, Shinozuka O, et al. Hinokitiol inhibits Candida Albicans adherence to oral epithelial cells. J Oral Biosci. 2010;52:42–50. doi: 10.1016/S1349-0079(10)80007-6. [DOI] [Google Scholar]
- 23.Sato N, Nakamura M, Senpuku H, Yamazaki T. The antibacterial action of the oral care blend hinokitiol. DENTAL. DIAMOND. 2008;33:164–168. [Google Scholar]
- 24.Tosaka C, Tajima H, Inoue T, Omoya M, Kobayashi M, Miura H, et al. Investigation of how to prevent mucositis induced by chemoradiotherapy. Japanese journal of cancer and. Chemotherapy. 2011;38:1647–1651. [PubMed] [Google Scholar]
- 25.Yamamoto T, Yoshimuta Y, Nokubi T, Yasui S, Kusunoki C, Nokubi H, et al. Clinical study of the relationship between different methods of masticatory function measurement and intraoral factors. The Japanese journal of mastication science and. Health Promotion. 2013;23:30–38. [Google Scholar]
- 26.Hurukawa Y, Takita M, Takahashi S, Okada Y, Ikeda J, Setogawa K, et al. Relief of oral complaint on cancer patient : practice of taste and oral function. The Japanese journal of taste and smell research. 2011;18:491–4.27. [Google Scholar]
- 27.Takagi N. Rehabilitation of disuse atrophy; we think about correspondence of dentistry in accord with needs of the aged society denture, oral care, oral rehabilitation. The Journal of Ibaraki synthesis rehabilitation care. 2012;21:7–11. [Google Scholar]
- 28.Ohashi Y, Abe M, Ueda N. Use experience of the dexamethasone paste for the stomatitis radiation of patients with oral cancer. Journal of New Remedies & Clinics. 1981;30:832–838. [Google Scholar]
- 29.Agarie Y. The regimen method; digestive disease Inraoral inflammation. Clinic All-Round. 2008;57:947–949. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, by contacting the corresponding author, without breaching patient confidentiality.